Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: From bedside to bench and back again

Pharmacogenomics

Volumn 7, Issue 1, 2006, Pages 15-23

  Martin, Annalise ^a   Nolan, David ^a   Almeida, Coral Ann ^a   Rauch, Andri ^a,b   Mallal, Simon ^a,c  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF BERN   (Switzerland)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Abacavir; HIV; HLA B*5701; Nevirapine; Prospective genetic testing

Indexed keywords

ABACAVIR; ANTICONVULSIVE AGENT; BETA LACTAM ANTIBIOTIC; NEVIRAPINE; SULFAMETHOXAZOLE; SULFONAMIDE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTHRALGIA; BULLOUS SKIN DISEASE; CELL METABOLISM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; EXPERIENCE; GASTROINTESTINAL DISEASE; GENE LOCUS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETICS; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INCIDENCE; LETHARGY; LIVER TOXICITY; LONG TERM CARE; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PATCH TEST; PATIENT SELECTION; PHARMACOGENETICS; POINT OF CARE TESTING; PREDICTION; PRESCRIPTION; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOPHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV-1; HUMANS; NEVIRAPINE;

EID: 33644874692     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.1.15     Document Type: Review

References (48)

1. Hewitt RG: Abacavir hypersensitivity reaction. Clin. Infect. Dis. 34(8), 1137-1142 (2002).
2. Peyriere H, Guillernin V, Lotthe A et al.: Reasons for early abacavir discontinuation in HIV-infected patients. Ann. Pharmacother. 37, 1392-1397 (2003).
3. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
4. Escaut L, Liotier JY, Albengres E, Cherninot N, Vittecoq D: Abacavir rechallenge, has to be avoided in case of hypersensitivity reaction. AIDS 13, 1419-1420 (1999).
5. Peyrieere H, Nicolas J, Siffert M, Demoly P Hillaire-Buys D, Reynes J: Hypersensitivity related to abacavir in two members of a family. Ann. Pharmacother. 35(10), 1291-1292 (2001).
6. Symonds W, Cutreii A, Edwards M et al.: Risk factor analysis of hypersensitivity reactions to abacavir. Clin. Ther. 24(4), 565-573 (2002).
7. Dieterich DT, Robinson PA, Love J, Stem JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 38(Suppl. 2), S80-S89 (2004).
8. Stern JO, Robinson PA, Love J et al.: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir. Immune Defic. Syndr. 34(Suppl. 1), S21-S33 (2003).
9. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
10. Viramune (package insert). Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT USA, revised January 19 (2005).
11. Patel SM, Johnson S, Belknap SM et al.: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir. Immune. Defic. Syndr. 35(2), 120-125 (2004).
12. Mallal S, Nolan D, Witt C et al.: Association between the presence of HLA-B*5701, HLA-DRZ and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727 (2002).
13. Hetherington S, Hughes AR, Mostelle M, et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
14. Martin A, Nolan D, Gaudierl S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Horn variant. Proc. Natl Acad. Sci. USA 101, 4180-4185 (2004).
15. Hughes AR, Mosteller M, Bansal AT et al.: CNA30027 study team: CAN30032 study team. Association of genetic variation in HLA-B region with hypersensitivity to abacavir in some but not all, populations. Pharmacogenomics 5(2), 203-211 (2004).
16. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
17. Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence specific amplification: validation and comparison with sequence based typing. Tissue Antigens 65(6), 571-574 (2005).
18. Martin A, Nolan D, Rauch A, Almeida C, McKinnon E, Mallal S: Genetic screening for abacavir hypersensitivity (ABC-HSR) in the Western Australian cohort: prospective data and novel diagnostic approaches 17th Annual Conference of the Australasian Society for HIV medicine, p109 (2005).
19. Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S: A sensitive, rapid and cost-effective alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet. Genomics. (Manuscript submitted) (2005).
20. Nolan D, Gaudieri S, Mallal S: Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J. HIV Therapy 8(2), 36-41 (2003).
21. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16(16), 2223-2225 (2002).
22. Dinarello CA: Proinflammatory cytokines. Chest 118, 503-508.
23. Foster JR: The functions of cytokines and their uses in toxicology. J. Exp Path 92, 171-192 (2001).
24. Aziz N, Nishanian P Taylor JMG et al.: Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J. Infect. Dis. 179, 843-848 (1999).
25. Breen EC, McDonald M, Fan J, Boscardin J, Fahey JL: Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virus-infected persons. Clin. Diagnostic Lab. Immunol. 7, 769-773 (2000).
26. Jason J, Archibald LK, Nwanyanwu OC et al.: Comparison of serum and cell-specific cytokines in humans. Clin. Diagnostic Lab. Immunol. 8, 1097-1103 (2001).
27. House RV: Cytokine measurement techniques for assessing hypersensitivity. Toxicol. 158, 51-58 (2001).
28. Britschgi M, von Greyerz S, Burkhart C, Pichler WJ: Molecular aspects of drug recognition by specific T cells. Curr. Drug Targets 4, 1-11 (2003).
29. Martin AM, Nolan D, Gaudieri S, Phillips E, Malial S: Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics 5, 643-655 (2004).
30. Manchanda T, Hess D, Dale L, Ferguson SG, Rieder MJ: Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. 62, 1011-1026 (2002).
31. Zanni MP, Schnyder B, von Greyerz S, Pichler WJ: Involvement of T cells in drug-induced allergies. Trends Pharmacol. Sci. 23, 308-310 (1998).
32. Pirmohamed M, Naisbitt Dj, Gordon F, Park BK: The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicol. 181-182, 55-63 (2002).
33. Coleman JW: Protein haptenation by drugs. Clin. Exp. Allergy 28(Suppl. 4), 79-82 (1998).
34. Sallusto F, Lanzavecchia A, Mackay CR: Chemokines and chemokine receptors in T-cell priming and Th1/Th2 responses. Immunol. Today 19, 568-574 (1998).
35. Naisbitt Dj, Britschgi M, Wong G et al.: Hypersensitivity reactions to carbamazepine: Characterization of the specificity, phenotype, and cytokine profile of drug specific T cell clones. Mol. Pharmacol. 63, 732-741 (2003).
36. Parkin J, Cohen B: An overview of the immune system. Lancet 357, 1777-1789 (2001).
37. Jarnicki AG, Fallon PG: T helper type-2 cytokine responses: potential therapeutic targets. Curr. Opin. Pharmacol. 3, 449-455 (2003).
38. 2 responses to drugs. Taxicol. 158, 25-29 (2001).
39. Lucey DR, Clerict M, Shearer GM: Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and imflammatory diseases. Clin. Microbiol. Rev. 9, 532-562 (1996).
40. Spellberg B, Edwards JE Jr: Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 32, 76-102 (2001).
41. Opal SM, DePalo VA: Anti-inflammmatory cytokines. Chest 117, 1162-1172 (2000).
42. Merk HF: Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicol. 209, 217-220 (2005).
43. Mauri-Hellweg D, Bettens F, Mauri D et al.: Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 155, 452-472 (1995)
44. Padovan E, von Greyerz S, Pichler WJ et al.: Antigen-dependent and -independent IFN-γ modulation by penicillins. J. Immunol. 162, 1171-1177 (1999).
45. Guest I, Sokoluk B, MacCrimmon J et al.: Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131, 53-65 (1998).
46. Phillips EJ, Wong GA, Kaui R et al.: Clinical and immunogenetic correlates: of abacavir hypersensitivity. AIDS 19, 979-987 (2005).
47. Watson ME, Pimenta JM, Spreen WR, Hernandez JE: HLA-B*5701 and abacavir hypersensitivity. Pharmacogenetics 14(11), 783 (2004).
48. + T cell counts. AIDS 19 (1), 97-99 (2005).